Physician profile
Jose E Paz
NPI 1588620504
$5,066.87
in general payments reported to CMS, 2019-2025
38 companies · $889 in 2025
The $889 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $825 · 2020: $584 · 2021: $486 · 2022: $439 · 2023: $854 · 2024: $990 · 2025: $889.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,732.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,732.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,057.17 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $749.89 | 2019-2025 | Farxiga, Lokelma, Airsupra |
| Lilly USA, LLC | $684.21 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbott Laboratories | $418.85 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2, Eterna |
| Amgen INC. | $390.48 | 2019-2024 | Prolia, Evenity, Otezla |
| Abbvie INC. | $208.89 | 2022-2025 | |
| Pfizer INC. | $192.75 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $177.82 | 2019-2024 | Gardasil, Capvaxive, Gardasil 9 |
| Glaxosmithkline, LLC. | $122.61 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Otsuka America Pharmaceutical, INC. | $93.85 | 2023-2025 | Rexulti, Jynarque |
| Bayer Healthcare Pharmaceuticals INC. | $76.77 | 2022-2024 | |
| Astellas Pharma US INC | $64.03 | 2023-2025 | Veozah |
| Dexcom, INC. | $63.94 | 2021-2022 | |
| Xeris Pharmaceuticals, INC. | $58.89 | 2022-2023 | Gvoke Hypopen |
| Boehringer Ingelheim Pharmaceuticals, INC. | $58.43 | 2023-2025 | Jardiance |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jose Paz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.